Shares of Intec Pharma Ltd (NASDAQ:NTEC) have received a consensus recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $11.60.
A number of equities research analysts have recently issued reports on NTEC shares. Zacks Investment Research lowered shares of Intec Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. BidaskClub lowered shares of Intec Pharma from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 16th. LADENBURG THALM/SH SH restated a “buy” rating and issued a $12.00 target price on shares of Intec Pharma in a research note on Tuesday, January 29th. ValuEngine upgraded shares of Intec Pharma from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Maxim Group restated a “buy” rating and issued a $12.00 target price on shares of Intec Pharma in a research note on Tuesday, February 19th.
Shares of NTEC stock opened at $5.86 on Tuesday. Intec Pharma has a 12 month low of $3.55 and a 12 month high of $9.25. The firm has a market capitalization of $185.82 million, a price-to-earnings ratio of -4.19 and a beta of 0.29.
Intec Pharma (NASDAQ:NTEC) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities analysts expect that Intec Pharma will post -1.11 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of NTEC. Delek Group Ltd. purchased a new stake in Intec Pharma during the 1st quarter valued at about $154,000. Knott David M raised its holdings in Intec Pharma by 2.5% in the 1st quarter. Knott David M now owns 290,434 shares of the biotechnology company’s stock worth $2,129,000 after purchasing an additional 6,961 shares during the period. Private Advisors LLC acquired a new position in Intec Pharma in the 1st quarter worth about $225,000. Dimensional Fund Advisors LP acquired a new position in Intec Pharma in the 1st quarter worth about $182,000. Finally, Sigma Planning Corp acquired a new position in Intec Pharma in the 1st quarter worth about $183,000. Institutional investors and hedge funds own 34.72% of the company’s stock.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.